supp.fit

Larch

4 benefits mapped to clinical evidence across supplements.

Benefit Evidence

Antibody boost +8.08

Cold incidence -

Tetanus IgG +

324 people

Lesions, +56% responders

Discomfort, +21% healed

186 people

Fewer colds

Worse onset symptoms

199 people

Fewer colds, +p=0.038

Higher onset severity, +p=0.028

199 people

Research sources

Immune support (3)
  1. Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers

    PubMed ID: 20796315

    Randomized human pilot (ResistAid™) increased specific pneumococcal IgG subtypes versus placebo—robust adaptive immune signal for bacterial antigens.

  2. Larch arabinogalactan effects on reducing incidence of upper respiratory infections

    PubMed ID: 23339578

    Large RCT showed fewer participants developed colds, supporting enhanced resistance to common respiratory infections.

  3. Immunomodulatory effects of ResistAidâ„¢: A randomized, double-blind, placebo-controlled, multidose study

    PubMed ID: 24219376

    Dose-ranging RCT showed significantly higher tetanus IgG at 1.5 g/day versus placebo, supporting selective enhancement of vaccine responses.

Skin appearance (2)
  1. Turpentine Ointment for the Treatment of Folliculitis: An Open, Prospective, Randomized, Placebo- and Comparator-Controlled Multicenter Trial

    PubMed ID: 38104550

    Small randomized trial of a larch turpentine-containing ointment showed improved folliculitis patient-reported outcomes and responder rate versus placebo.

  2. Turpentine Ointment in Bacterial Skin Infections: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial

    PubMed ID: 36417842

    Randomized trial of a turpentine/larch resin ointment improved healing and discomfort in skin abscesses, supporting topical larch-derived benefit for skin recovery/appearance.

Daily comfort (1)
  1. Larch arabinogalactan effects on reducing incidence of upper respiratory infections

    PubMed ID: 23339578

    12-week RCT showing fewer colds supports a role for larch arabinogalactan in reducing seasonal respiratory illness burden.

Respiratory comfort (1)
  1. Larch arabinogalactan effects on reducing incidence of upper respiratory infections

    PubMed ID: 23339578

    Large randomized trial showed fewer participants experienced common colds over 12 weeks with larch arabinogalactan, supporting reduced respiratory infection risk.

Similar by evidence

Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.

Products with Larch

Search all

3 products whose verified label declares Larch — not every bottle that mentions it in a title.